Purpose: The purpose of this study is to develop a model to predict clinical response to and sustained clinical remission following treatment with vedolizumab and ustekinumab in pediatric patients with Ulcerative Colitis (UC) who have previously been exposed to anti-TNF therapy.
Specific Aims:
Objective: To identify baseline predictors of remission and response to vedolizumab and ustekinumab to assist providers in determining therapeutic options in pediatric patients with Ulcerative Colitis who have failed anti-TNF therapy.
Sub Aim 1: Remission rate at 12 weeks, defined as PUCAI < 10.
Sub Aim 2: Response rate at 12 weeks, defined as an improvement in PUCAI > 20.
Sub Aim 3: Sustained remission and response rates at 52 weeks.
Sub Aim 4: Corticosteroid free remission and response rates at weeks 12 and 52.
Study Period: July 2020-July 2022
Contact: Perseus Patel